REPEATED DOSES OF LPJ-394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

这是一项前瞻性、多中心、双盲、安慰剂对照研究。 II-III期试验，其中一种研究性新药LPJ 394将 测试其减少抗体产生的能力， 双链DNA（抗dsDNA），并限制活动性肾 狼疮性肾炎的症状有哪些？ 受试者将接受 药物治疗52周，之后将有一个六个月的周期， 随访期间评估临床狼疮活动，抗DNA水平 和健康状况。

This is a prospective multi-center double-blind, placebo-controlled Phase II-III trial in which an investigational new drug, LPJ 394, will be tested for its ability to reduce the production of antibodies to double stranded DNA (anti-dsDNA) and limit flare-ups of active renal disease in patients with lupus nephritis. The subjects will receive medication for 52 weeks, after which there will be a six month periiod of follow-up period to assess clinical lupus activity, anti-DNA levels and health status.